Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy

Shigeo Fuji; Arnon Nagler; Mohamad Mohty; Bipin Savani; Roni Shouval

doi:10.1038/s41409-020-0784-x

Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy

Shigeo Fuji, Arnon Nagler, Mohamad Mohty, Bipin Savani, Roni Shouval

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment available for various hematological malignancies. Ideally, prospective randomized controlled trials (RCTs) should establish the indications for allo-HSCT. In reality, however, RCTs are not feasible due to the rarity of many hematological conditions. In these scenarios, decision analysis, which simulates possible outcomes with different approaches, can help in selecting the treatment strategy predicted to have the best result. Assessment of cost-effectiveness can also be incorporated in computational simulation analysis. In this review, we would like to provide an overview of decision-analytic models that evaluate alternative treatment strategies for patients with hematological malignancies.

Original language	English
Pages (from-to)	1220-1228
Number of pages	9
Journal	Bone Marrow Transplantation
Volume	55
Issue number	7
DOIs	https://doi.org/10.1038/s41409-020-0784-x
State	Published - 1 Jul 2020
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.

Funding

Acknowledgements This study was supported by Health, Labour, and Welfare Science Grants for Research on Measures for Rare and Intractable Diseases from the Japanese Government.

Funders	Funder number
Japanese Government
Welfare Science

Access to Document

10.1038/s41409-020-0784-x

Cite this

@article{414e054911b542ecbd832f815bda98b0,

title = "Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy",

abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment available for various hematological malignancies. Ideally, prospective randomized controlled trials (RCTs) should establish the indications for allo-HSCT. In reality, however, RCTs are not feasible due to the rarity of many hematological conditions. In these scenarios, decision analysis, which simulates possible outcomes with different approaches, can help in selecting the treatment strategy predicted to have the best result. Assessment of cost-effectiveness can also be incorporated in computational simulation analysis. In this review, we would like to provide an overview of decision-analytic models that evaluate alternative treatment strategies for patients with hematological malignancies.",

author = "Shigeo Fuji and Arnon Nagler and Mohamad Mohty and Bipin Savani and Roni Shouval",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2020",

month = jul,

day = "1",

doi = "10.1038/s41409-020-0784-x",

language = "אנגלית",

volume = "55",

pages = "1220--1228",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "7",

}

TY - JOUR

T1 - Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy

AU - Fuji, Shigeo

AU - Nagler, Arnon

AU - Mohty, Mohamad

AU - Savani, Bipin

AU - Shouval, Roni

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment available for various hematological malignancies. Ideally, prospective randomized controlled trials (RCTs) should establish the indications for allo-HSCT. In reality, however, RCTs are not feasible due to the rarity of many hematological conditions. In these scenarios, decision analysis, which simulates possible outcomes with different approaches, can help in selecting the treatment strategy predicted to have the best result. Assessment of cost-effectiveness can also be incorporated in computational simulation analysis. In this review, we would like to provide an overview of decision-analytic models that evaluate alternative treatment strategies for patients with hematological malignancies.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment available for various hematological malignancies. Ideally, prospective randomized controlled trials (RCTs) should establish the indications for allo-HSCT. In reality, however, RCTs are not feasible due to the rarity of many hematological conditions. In these scenarios, decision analysis, which simulates possible outcomes with different approaches, can help in selecting the treatment strategy predicted to have the best result. Assessment of cost-effectiveness can also be incorporated in computational simulation analysis. In this review, we would like to provide an overview of decision-analytic models that evaluate alternative treatment strategies for patients with hematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85077978391&partnerID=8YFLogxK

U2 - 10.1038/s41409-020-0784-x

DO - 10.1038/s41409-020-0784-x

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 31932655

AN - SCOPUS:85077978391

SN - 0268-3369

VL - 55

SP - 1220

EP - 1228

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 7

ER -

Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy

Abstract

Bibliographical note

Funding

Access to Document

Other files and links

Fingerprint

Cite this